{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?page=16&q=gastroesophageal+junction", "query": { "q": "gastroesophageal junction", "page": 16 }, "page_size": 10 }, "pagination": { "page": 16, "page_size": 10, "total_count": 518, "total_pages": 52, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=17&q=gastroesophageal+junction&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=15&q=gastroesophageal+junction&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T04:15:29.049Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06764875", "title": "A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HER2-positive Gastric Cancer", "Gastroesophageal Junction Adenocarcinoma" ], "interventions": [ { "name": "Rilvegostomig", "type": "DRUG" }, { "name": "Trastuzumab deruxtecan", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "5-fluorouracil", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 840, "start_date": "2025-03-01", "completion_date": "2030-12-09", "has_results": false, "last_update_posted_date": "2026-09-11", "last_synced_at": "2026-10-14T04:15:29.049Z", "location_count": 58, "location_summary": "Anchorage, Alaska • Phoenix, Arizona • Duarte, California + 51 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Alamitos", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06764875" }, { "nct_id": "NCT00716157", "title": "Incidence and Patterns of Nausea/Vomiting With Combined Chemotherapy and Radiation", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cancer of the Head and Neck", "Cancer of the Lung", "Cancer of the Esophagus", "Gastro-esophageal Junction Cancer" ], "interventions": [], "intervention_types": [], "sponsor": "Thomas Jefferson University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2004-10", "completion_date": "2011-09", "has_results": false, "last_update_posted_date": "2014-12-05", "last_synced_at": "2026-10-14T04:15:29.049Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00716157" }, { "nct_id": "NCT02434705", "title": "Food Antigen in Eosinophilic Esophagitis", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Eosinophilic Esophagitis" ], "interventions": [ { "name": "Antigen (wheat base soy sauce) spray", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 72, "start_date": "2015-04-01", "completion_date": "2023-12-08", "has_results": false, "last_update_posted_date": "2023-12-12", "last_synced_at": "2026-10-14T04:15:29.049Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02434705" }, { "nct_id": "NCT00711412", "title": "Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients With Esophageal or Gastroesophageal Junction Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Esophageal Cancer" ], "interventions": [ { "name": "Induction Therapy - Capecitabine", "type": "DRUG" }, { "name": "Induction Therapy - Oxaliplatin", "type": "DRUG" }, { "name": "Combination Therapy - Capecitabine", "type": "DRUG" }, { "name": "Combination Therapy - Oxaliplatin", "type": "DRUG" }, { "name": "Combination Therapy - Radiation", "type": "RADIATION" }, { "name": "Evaluation for response and surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 44, "start_date": "2006-05-31", "completion_date": "2013-01-30", "has_results": true, "last_update_posted_date": "2018-07-18", "last_synced_at": "2026-10-14T04:15:29.049Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00711412" }, { "nct_id": "NCT05329766", "title": "A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastrointestinal Tract Malignancies" ], "interventions": [ { "name": "Domvanalimab", "type": "DRUG" }, { "name": "Quemliclustat", "type": "DRUG" }, { "name": "Zimberelimab", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Arcus Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 332, "start_date": "2022-06-10", "completion_date": "2027-06", "has_results": false, "last_update_posted_date": "2026-09-29", "last_synced_at": "2026-10-14T04:15:29.049Z", "location_count": 17, "location_summary": "Phoenix, Arizona • Los Angeles, California • Santa Monica, California + 12 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Derby", "state": "Connecticut" }, { "city": "Fort Myers", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05329766" }, { "nct_id": "NCT06445972", "title": "Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Gastroesophageal Junction", "Gastroesophageal Adenocarcinoma", "Esophageal Neoplasms", "Esophageal Cancer" ], "interventions": [ { "name": "Ramucirumab", "type": "BIOLOGICAL" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Sacituzumab Tirumotecan", "type": "BIOLOGICAL" }, { "name": "Rescue Medications", "type": "DRUG" }, { "name": "HER3-DXd", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 210, "start_date": "2024-08-07", "completion_date": "2030-08-08", "has_results": false, "last_update_posted_date": "2026-09-03", "last_synced_at": "2026-10-14T04:15:29.049Z", "location_count": 8, "location_summary": "Tucson, Arizona • Los Angeles, California • Louisville, Kentucky + 5 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "East Syracuse", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06445972" }, { "nct_id": "NCT04847466", "title": "Immunotherapy Combination: Irradiated PD-L1 CAR-NK Cells Plus Pembrolizumab Plus N-803 for Subjects With Recurrent/Metastatic Gastric or Head and Neck Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastroesophageal Junction (GEJ) Cancers", "Advanced HNSCC" ], "interventions": [ { "name": "N-803", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "PD-L1 t-haNK", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 18, "start_date": "2021-12-14", "completion_date": "2026-01-06", "has_results": false, "last_update_posted_date": "2026-06-01", "last_synced_at": "2026-10-14T04:15:29.049Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04847466" }, { "nct_id": "NCT03406975", "title": "Multicenter Endoscopic Sleeve Gastrectomy (ESG) Trial (MERIT Trial)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Obesity", "Hypertension", "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Overstitch Endoscopic Suture System", "type": "DEVICE" }, { "name": "Lifestyle Intervention", "type": "BEHAVIORAL" } ], "intervention_types": [ "DEVICE", "BEHAVIORAL" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "21 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "21 Years to 65 Years" }, "enrollment_count": 208, "start_date": "2017-12-20", "completion_date": "2021-10-15", "has_results": true, "last_update_posted_date": "2022-10-18", "last_synced_at": "2026-10-14T04:15:29.049Z", "location_count": 9, "location_summary": "Orlando, Florida • Chicago, Illinois • Evanston, Illinois + 6 more", "locations": [ { "city": "Orlando", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Evanston", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03406975" }, { "nct_id": "NCT04095273", "title": "Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "Elimusertib (BAY1895344)", "type": "DRUG" }, { "name": "Pembrolizumab (Keytruda®)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 56, "start_date": "2019-09-30", "completion_date": "2023-04-11", "has_results": false, "last_update_posted_date": "2024-04-02", "last_synced_at": "2026-10-14T04:15:29.049Z", "location_count": 8, "location_summary": "Palo Alto, California • New Haven, Connecticut • Baltimore, Maryland + 5 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04095273" }, { "nct_id": "NCT04060342", "title": "GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Adenocarcinoma", "Esophageal Adenocarcinoma", "Esophageal Squamous Cell Carcinoma", "Gastric Adenocarcinoma", "Gastroesophageal Junction Adenocarcinoma", "Triple Negative Breast Cancer", "Castration-resistant Prostate Cancer", "Microsatellite Stable Colorectal Cancer", "Non-small Cell Lung Cancer", "Small-cell Lung Cancer", "Head and Neck Squamous Cell Carcinoma", "Urothelial Carcinoma", "Renal Cell Carcinoma", "Hepatocellular Carcinoma" ], "interventions": [ { "name": "GB1275", "type": "DRUG" }, { "name": "nab-paclitaxel and gemcitabine", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 61, "start_date": "2019-08-13", "completion_date": "2022-04-11", "has_results": false, "last_update_posted_date": "2022-08-18", "last_synced_at": "2026-10-14T04:15:29.049Z", "location_count": 7, "location_summary": "San Francisco, California • Aurora, Colorado • St Louis, Missouri + 4 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04060342" } ] }